OpenAI has brought Codex preview controls to the ChatGPT mobile app, letting iPhone and Android users review, approve, and ...
Arcus Biosciences (RCUS) traded lower in the premarket on Monday after the oncology-focused biotech announced the discontinuation of a late-stage trial designed to evaluate its anti-TIGIT therapy ...
Add Outdoor Life (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. A ...
Arcobi combines 25 years of power market data with AI forecasting and automated execution, serving energy traders, generation operators, and commercial and industrial organizations. CALGARY, AB, March ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
At least two additional data presentations for casdatifan are expected in 2026: updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer In addition to the ongoing ...
Arcus Infrastructure Partners will acquire Wifinity, a UK-based internet managed services provider, from LDC and Literacy Capital. Literacy will generate a total expected return of 5.2x MoM, in line ...
Arcus Biosciences develops and advances oncology therapies, including Etrumadenant (A2a/A2b antagonist), Zimberelimab (anti-PD-1 antibody), Domvanalimab (anti-TIGIT antibody), Quemliclustat (CD73 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results